Literature DB >> 3035045

Measurement of circulating corticotrophin-releasing factor in man.

D Cunnah, D S Jessop, G M Besser, L H Rees.   

Abstract

A radioimmunoassay was developed to measure corticotrophin-releasing factor (CRF-41) extracted from human plasma using Vycor glass. Assay sensitivity was 20 ng/l and intra- and interassay coefficients of variation were 10.2 and 11.4% respectively. The normal range of plasma CRF-41 was less than 20-110 ng/l (n = 46). Plasma concentrations of CRF-41 in patients with Cushing's disease. Nelson's syndrome and Addison's disease were within the normal range. No correlation was found between CRF-41 and ACTH in these syndromes. Two patients with the ectopic ACTH syndrome had increased plasma concentrations of CRF-41. In normal subjects no changes in plasma CRF-41 occurred after insulin-induced hypoglycaemia, treatment with dexamethasone or feeding, and changes in the concentrations of CRF-41 did not reflect circadian changes in plasma concentrations of cortisol. Concentrations of immunoreactive CRF in plasma of women in the third trimester of pregnancy were increased (550-9300 ng/l) and gel filtration chromatography showed that this comprised CRF-41 and a higher molecular weight form. Reversed-phase high-performance liquid chromatography also revealed multiple peaks of immunoreactive CRF in extracts of plasma and placenta.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3035045     DOI: 10.1677/joe.0.1130123

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  9 in total

1.  Girls with virilisation in childhood: a diagnostic protocol for investigation.

Authors:  M E Street; A Weber; C Camacho-Hübner; L A Perry; C E Brain; A M Cotterill; M O Savage
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

2.  Lack of preservation of higher brain function during hypoglycaemia in patients with intensively-treated IDDM.

Authors:  A Maran; J Lomas; I A Macdonald; S A Amiel
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

3.  The effect of modafinil on counter-regulatory and cognitive responses to hypoglycaemia.

Authors:  D Smith; A Pernet; J M Rosenthal; E M Bingham; H Reid; I A Macdonald; S A Amiel
Journal:  Diabetologia       Date:  2004-10-23       Impact factor: 10.122

4.  Immunosuppressive activity of corticotrophin-releasing factor. Inhibition of interleukin-1 and interleukin-6 production by human mononuclear cells.

Authors:  P Hagan; S Poole; A F Bristow
Journal:  Biochem J       Date:  1992-01-01       Impact factor: 3.857

5.  Metyrapone induced increase in plasma corticotropin is not associated with changes in peripheral venous arginine vasopressin or corticotropin releasing factor.

Authors:  S J Holmes; C M Florkowski; M J Evans; M J Ellis; J H Livesey; R A Donald; E A Espiner
Journal:  J Endocrinol Invest       Date:  1993-11       Impact factor: 4.256

6.  Steroid hormone abnormalities in women with severe idiopathic constipation.

Authors:  M A Kamm; M J Farthing; J E Lennard-Jones; L A Perry; T Chard
Journal:  Gut       Date:  1991-01       Impact factor: 23.059

7.  4-hydroxyandrostenedione--further clinical and extended endocrine observations.

Authors:  T Pickles; L Perry; P Murray; P Plowman
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

8.  Abnormalities in Glucose Metabolism, Appetite-Related Peptide Release, and Pro-inflammatory Cytokines Play a Central Role in Appetite Disorders in Peritoneal Dialysis.

Authors:  Lorena Avila-Carrasco; Mario A Pavone; Elena González; Álvaro Aguilera-Baca; Rafael Selgas; Gloria Del Peso; Secundino Cigarran; Manuel López-Cabrera; Abelardo Aguilera
Journal:  Front Physiol       Date:  2019-05-28       Impact factor: 4.566

9.  Molecular reductions in glucokinase activity increase counter-regulatory responses to hypoglycemia in mice and humans with diabetes.

Authors:  Ali J Chakera; Paul S Hurst; Gill Spyer; Emmanuel O Ogunnowo-Bada; William J Marsh; Christine H Riches; Chen-Yu Yueh; S Pauliina Markkula; Jeffrey W Dalley; Roger D Cox; Ian A Macdonald; Stephanie A Amiel; Kenneth M MacLeod; Lora K Heisler; Andrew T Hattersley; Mark L Evans
Journal:  Mol Metab       Date:  2018-08-13       Impact factor: 7.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.